Following Vertex pact, Parion strikes another rich collaboration — this time with Shire
Two years after Durham, NC-based Parion Sciences forged a major tie-up with Vertex on cystic fibrosis, the little biotech has done it again — this time with Shire.
Lexington, MA-based Shire has agreed to pay $40 million in an upfront and near-term cash to get its hands on worldwide rights to a Phase II dry eye disease drug. Hundreds of millions more is on the table in promised milestones, bringing the potential deal value up to $535 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
